Open AccessINCREASE IN NKT CELLS – A MARKER OF EARLY PROGRESSING AT ADJUVANTVACCINOTHERAPY OF PATIENTS WITH A METASTATIC MELANOMA OF SKIN
Author(s) -
А А Борунова,
Г. З. Чкадуа,
Т. Н. Заботина,
З. Г. Кадагидзе,
О. В. Короткова,
А. И. Черткова,
D Tabakov,
Е. Н. Захарова,
Э. К. Шоуа,
Н. Н. Петенко,
Лев В. Демидов,
И. Н. Михайлова
Publication year - 2019
Publication title -
rossijskij bioterapevtičeskij žurnal
Language(s) - English
Resource type - Journals
eISSN - 1726-9792
pISSN - 1726-9784
DOI - 10.17650/1726-9784-2019-18-4-82-89
Subject(s) - medicine , melanoma , natural killer t cell , adjuvant , immune system , immunotherapy , regimen , adjuvant therapy , immunology , cancer , oncology , cancer research , t cell
. Natural killer T lymphocytes (NKT) take place between the innate and acquired immune response. The ability of these cells to activate the antitumor immune response and inhibit immunological activity makes them the target of research in cancer patients. The radicality of surgical treatment of patients with metastatic melanoma (stage III–IV) is relatively conventional. In this regard, the possibility of adjuvant effective therapy of melanoma is actively investigated worldwide. The aim of the study is investigation of the importance of increasing the number of NKT cells in the peripheral blood of patients with metastatic melanoma after radical surgical removal of the tumor. Patients were treated with adjuvant regimen antitumor autologous dendritic cell therapy in form of vaccination. Materials and methods . The study included 39 patients with stage III and IV metastatic melanoma with regional and / or distant metastases after radical surgery. From the peripheral blood monocytes of each patient, an autologous vaccine was created from mature dendritic cells loaded with tumor lysate. The therapy continued until objective progression. The study included patients who received from 5 to 120 injections. The follow-up period ranged from 5 to 168 months. Results . It was shown that 14 (36 %) of patients had the number of NKT cells exceeding the norm (0–10 %) and in the course of vaccine therapy they had the progression of the disease in the period up to 2 years. In patients with relapse-free course of the disease in vaccine therapy (n = 13), the number of NKT lymphocytes did not exceed the norm both before and during therapy. Significantly shorter time to progression was revealed in patients with high initial content of NKT lymphocytes compared with patients with normal indices of NKT cells (6.5 months) – 95 % confidence limit 2,4–10,7 % vs 96,2 months (95 % confidence limit 63.8–128.6 %). Conclusion . An increased number of NKT cells in patients with stage III–IV metastatic melanoma after radical surgical treatment is a marker of early progression.